X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16240) 16240
Publication (1032) 1032
Book Review (91) 91
Newsletter (51) 51
Book / eBook (27) 27
Book Chapter (22) 22
Magazine Article (17) 17
Conference Proceeding (12) 12
Newspaper Article (7) 7
Dissertation (6) 6
Reference (2) 2
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14762) 14762
recombinant proteins (10374) 10374
male (8551) 8551
female (8192) 8192
interferon-alpha - therapeutic use (8130) 8130
middle aged (6986) 6986
adult (6628) 6628
antiviral agents - therapeutic use (4959) 4959
hepatitis c, chronic - drug therapy (4335) 4335
index medicus (4250) 4250
interferon-alpha - administration & dosage (3990) 3990
treatment outcome (3928) 3928
drug therapy, combination (3813) 3813
aged (3581) 3581
ribavirin - therapeutic use (3453) 3453
polyethylene glycols - therapeutic use (3339) 3339
interferon (3163) 3163
interferon-alpha - adverse effects (3073) 3073
gastroenterology & hepatology (2961) 2961
interferon alpha-2 (2355) 2355
recombinant proteins - therapeutic use (2308) 2308
therapy (2232) 2232
hepatitis c (2202) 2202
hepacivirus - genetics (2170) 2170
ribavirin (2012) 2012
antiviral agents - administration & dosage (1982) 1982
animals (1937) 1937
oncology (1888) 1888
genotype (1836) 1836
antiviral agents - adverse effects (1811) 1811
ribavirin - administration & dosage (1697) 1697
interferon-alpha (1598) 1598
hepatitis c - drug therapy (1513) 1513
polyethylene glycols - administration & dosage (1447) 1447
interferon-alpha - pharmacology (1399) 1399
hepatitis c, chronic - virology (1383) 1383
time factors (1371) 1371
hepatitis c virus (1366) 1366
immunology (1339) 1339
virus-infection (1308) 1308
adolescent (1254) 1254
viral load (1214) 1214
infection (1204) 1204
ribavirin - adverse effects (1174) 1174
biological response modifiers (1172) 1172
rna, viral - blood (1172) 1172
polyethylene glycols - adverse effects (1155) 1155
follow-up studies (1102) 1102
virology (1100) 1100
infectious diseases (1079) 1079
drug administration schedule (1068) 1068
hepacivirus - drug effects (1067) 1067
recombinant proteins - administration & dosage (1035) 1035
prospective studies (1011) 1011
mice (1006) 1006
care and treatment (1005) 1005
plus ribavirin (976) 976
pharmacology & pharmacy (975) 975
health aspects (960) 960
dose-response relationship, drug (927) 927
antineoplastic combined chemotherapy protocols - therapeutic use (910) 910
interferon type i - therapeutic use (881) 881
retrospective studies (874) 874
hepatitis c, chronic - complications (864) 864
polyethylene glycols (836) 836
antineoplastic agents - therapeutic use (798) 798
hepatitis (797) 797
medicine, general & internal (786) 786
hematology (776) 776
interferon alpha (773) 773
expression (758) 758
combination (747) 747
recurrence (739) 739
biochemistry & molecular biology (729) 729
combination therapy (723) 723
drug therapy (719) 719
combined modality therapy (713) 713
recombinant proteins - adverse effects (707) 707
cancer (702) 702
hepatitis b, chronic - drug therapy (697) 697
young adult (689) 689
chronic hepatitis-c (688) 688
analysis (687) 687
alpha (678) 678
chronic hepatitis c (668) 668
pegylated interferon (667) 667
recombinant proteins - pharmacology (661) 661
virus (651) 651
prognosis (649) 649
immunotherapy (648) 648
interferon type i - pharmacology (644) 644
alanine transaminase - blood (643) 643
hepacivirus - isolation & purification (639) 639
risk factors (635) 635
peginterferon alpha-2a (633) 633
antiviral agents - pharmacology (618) 618
hepatitis c - therapy (609) 609
research (608) 608
cell line (598) 598
hepatitis c - complications (554) 554
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (17) 17
UofT at Scarborough - Stacks (5) 5
Engineering & Comp. Sci. - Stacks (2) 2
UofT at Mississauga - Stacks (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
OISE - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14644) 14644
German (265) 265
Chinese (263) 263
Russian (247) 247
Spanish (218) 218
French (203) 203
Japanese (188) 188
Polish (75) 75
Italian (56) 56
Hungarian (43) 43
Korean (41) 41
Serbian (17) 17
Czech (15) 15
Croatian (14) 14
Dutch (14) 14
Portuguese (14) 14
Ukrainian (12) 12
Slovak (8) 8
Hebrew (5) 5
Finnish (4) 4
Danish (3) 3
Norwegian (3) 3
Romanian (3) 3
Arabic (2) 2
Bulgarian (2) 2
Swedish (2) 2
Turkish (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Annals of Hematology, ISSN 0939-5555, 04/2015, Volume 94, Issue 2, pp. 195 - 207
Interferon-alpha (IFN alpha) was once the standard of frontline treatment for chronic myeloid leukemia (CML). Its pleiotropic mechanism of action in CML... 
Imatinib | Chronic myeloid leukemia | Interferon-alpha | Tyrosine kinase inhibitor | Myeloproliferative neoplasms | CHRONIC MYELOGENOUS LEUKEMIA | BONE-MARROW-TRANSPLANTATION | CHRONIC HEPATITIS-C | EARLY CHRONIC-PHASE | CHRONIC MYELOID-LEUKEMIA | COMPLETE CYTOGENETIC REMISSION | GROWTH-INHIBITORY RESPONSES | HEMATOPOIETIC STEM-CELLS | LOW-DOSE CYTARABINE | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | Recombinant Proteins - therapeutic use | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Maintenance Chemotherapy - adverse effects | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology | Biomarkers - metabolism | Molecular Targeted Therapy - adverse effects | Immunologic Factors - administration & dosage | Interferon-alpha - therapeutic use | Remission Induction | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Animals | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Immunologic Factors - adverse effects | Interferon-alpha - adverse effects | Immunologic Factors - therapeutic use | Interferon | Biological response modifiers | Leukemia | Stem cells
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2012, Volume 58, Issue 2, pp. 225 - 233
Background & Aims A better understanding of the immunomodulatory effects of PegIFNα therapy could allow more rational optimisation of future therapeutic... 
Gastroenterology and Hepatology | IFN-α | NK cell receptors | TRAIL | eAg-negative CHB | CD56bright NK cells | T cells | PegIFNα-immunomodulatory | NK cells | CD56 | APOPTOSIS | CLEARANCE | NATURAL-KILLER-CELLS | CYTOKINES | CD56(bright) NK cells | INTERLEUKIN-12 | INDUCTION | PegIFN alpha-immunomodulatory | IFN-alpha | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | T-CELLS | Recombinant Proteins - therapeutic use | Interferon-alpha - pharmacology | CD8-Positive T-Lymphocytes - pathology | Hepatitis B, Chronic - immunology | Humans | Middle Aged | Male | Killer Cells, Natural - pathology | Polyethylene Glycols - therapeutic use | Immunity, Innate - physiology | CD8-Positive T-Lymphocytes - metabolism | Killer Cells, Natural - immunology | Adult | Female | Hepatitis B virus - immunology | Hepatitis B, Chronic - pathology | Polyethylene Glycols - pharmacology | Adaptive Immunity - physiology | Antiviral Agents - pharmacology | Immunity, Innate - drug effects | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Recombinant Proteins - pharmacology | Phenotype | Adaptive Immunity - drug effects | Hepatitis B, Chronic - drug therapy | CD56 Antigen | Interleukin-15 - metabolism | Cell Proliferation - drug effects | Killer Cells, Natural - metabolism | CD8-Positive T-Lymphocytes - immunology | Cohort Studies | Health aspects | Cells | Hepatitis B
Journal Article
Journal Article
Journal Article
Biological Psychiatry, ISSN 0006-3223, 2007, Volume 62, Issue 11, pp. 1324 - 1333
Journal Article
SEMINARS IN ONCOLOGY, ISSN 0093-7754, 08/2015, Volume 42, Issue 4, pp. 539 - 548
Efforts over nearly four decades have focused on ways to use cytokines to manipulate the host immune response towards cancer cell recognition and eradication.... 
PHASE-III TRIAL | METASTATIC MELANOMA | RECOMBINANT HUMAN INTERLEUKIN-12 | NATURAL-KILLER-CELLS | DENDRITIC CELLS | ONCOLOGY | HIGH-RISK | REGULATORY T-CELLS | ADJUVANT THERAPY | HIGH-DOSE INTERLEUKIN-2 | RENAL-CELL CARCINOMA
Journal Article
Journal Article
Journal Article